Bibliography
- Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
- Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007;30:1344-50
- Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-9
- Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58:389-462
- Laurent D, Gounarids JS, Gao J, Boettcher BR. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. Diabetes Obes Metab 2009;11:632-6
- Acton JJ III, Akiyama TE, Changet CH, et al. Discovery of (2R)-2-(3-{3-[(4-methoxyphenyl) carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor g modulator for the treatment of Type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume. J Med Chem Article ASAP Publication Date (Web): June 9 2009
- Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmaco Exp Ther 2007;320:323-30
- Bickel M, Brummerhop H, Fricket W. Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung 2008;58:574-80
- Kaddai V, Gonzalez T, Bolla M, Marchand-Brustel YL. CORMONTET: the nitric oxide-donating derivative of acetylsalicylic acid, NCX 4016, stimulates glucose transport and glucose transporters translocation in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2008;295:E162-9
- Hermansen K, Rommemaa T, Petersen AH, et al. Intensive therapy with inhaled insulin via the AERx Insulin Diabetes Management System: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004;27:162-7
- Gambero G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002;13:1615-25
- Hanft JR, Pollak RA, Barbul A, et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J Wound Care 2008;17:30-2, 34-7
- Hill MN, Gorzalka BB. Impairments in endocannabinoid signaling and depressive illness. JAMA 2009;301:1165-6
- Addy C, Li S, Agrawal N, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. J Clin Pharmacol 2008;48:418-27
- Dow RL, Caroino PA, Hadcoclet JR, et al. Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. J Med Chem 2009;52:2652-5
- Davidson MH. Squalene synthase inhibition: a novel target for the treatment of dislidemia. Curr Atheroscler Rep 2007;9:78-80
- Thornton SJ, Warburton C, Wasan KM, Kozlowski P. Disodium ascorbyl phytostanol phosphate (FM-VP4) is a cholesterol absorption inhibitor, a new class in cholesterol-lowering drug. Drug Dev Ind Pharm 2007;33:1058-69
- The Pharmaprojects database. Informa UK; 2009